A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets

PURPOSE: This study was designed to characterize the pharmacokinetic profile and to assess bioequivalence of the sponsor’s test formulation (imatinib mesylate 400 mg tablets) with an innovator product (Gleevec 400 mg tablets, Novartis Pharmaceuticals) under fed conditions, in adult patients of Phila...

Descripción completa

Detalles Bibliográficos
Autores principales: Arora, Rachna, Sharma, Manju, Monif, Tausif, Iyer, Sunil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946363/
https://www.ncbi.nlm.nih.gov/pubmed/26875198
http://dx.doi.org/10.4143/crt.2015.436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946363/
https://www.ncbi.nlm.nih.gov/pubmed/26875198
http://dx.doi.org/10.4143/crt.2015.436

Ejemplares similares